Sachiyo Minegishi

Sachiyo Minegishi is the Chief Operating Officer at Rectify. Prior to Rectify, Sachiyo served as Chief Financial Officer at Akouos, Inc., where she helped lead the acquisition of the company by Eli Lily.

Previously, Sachiyo was Vice President, Global Program Lead at bluebird bio and in charge of leading a cross-functional team through global development for a portfolio of gene therapies for Sickle Cell Disease. Earlier, Sachiyo held leadership roles at Aegerion Pharmaceuticals, Human Genome Sciences, Genzyme, and Amgen. Sachiyo began her career in investment banking at Merrill Lynch, with a focus on the execution of equity financing and mergers and acquisitions in the biotechnology industry. Sachiyo earned a B.S. in Chemical Engineering and Economics from the Massachusetts Institute of Technology and an M.B.A. from the Wharton School of the University of Pennsylvania.